Saframycin S, a new saframycin group antibiotic.

Publisher Website
Google Scholar
Abstract
Saframycin S, structurally the decyano-saframycin A and biosynthetically the precursor of saframycin A, is a new antibiotic and is presumably the active principle for the formation of the antibiotic-DNA complex to manifest its activity. The antibiotic had marked activity against Ehrlich ascites tumor cells in doses of 0.5-0.75 mg/kg per day for 10 days, and the rate of 40 day survivors was 80-90%. This antibiotic was less effective against mouse leukemia P388 cells than saframycin A at the doses tested. Saframycin S also showed the highest antimicrobial activity, particularly against gram-positive bacteria, among the saframycin group antibiotics identified to date. The LD50 of saframycin S was 3.2 mg/kg (i.p.) for ddY mice. The biological activity and toxicity of saframycin S in relation to its structure were described.